Early clinical development of tazarotene.

Abstract

Initial clinical investigations on tazarotene, a new acetylenic retinoid, have suggested potential usefulness in the treatment of mild-to-moderate plaque psoriasis. Tazarotene promotes healing of psoriatic lesions by modulating the key pathogenetic factors in this disease. It is not sensitizing, phototoxic, or photoallergenic, but causes moderate dose-related skin irritation. Systemic absorption is minimal and elimination is rapid, providing a low potential for systemic adverse effects. Tazarotene effectively treats mild-to-moderate plaque-type psoriasis, the benefits seem to be sustained after the cessation of therapy, and once-daily treatment is equally effective as more frequent application.

• Authors: R Marks
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 135 Suppl 49 Pg. 26-31 (Oct 1996) ISSN: 0007-0963 [Print] England
• PMID: 9035702 (Publication Type: Journal Article)

Chemical References

• Gels
• Nicotinic Acids
• Teratogens
• tazarotene

Topics

• Clinical Trials as Topic
• Gels
• Humans
• Nicotinic Acids (therapeutic use)
• Psoriasis (drug therapy, pathology)
• Randomized Controlled Trials as Topic
• Skin (drug effects, pathology)
• Teratogens (pharmacology)